TB 402

Drug Profile

TB 402

Alternative Names: Anti factor VIII monoclonal antibody LE 2E9; Mab LE 2E9; TB-402; TGX Krix-1

Latest Information Update: 12 Jun 2012

Price : $50

At a glance

  • Originator University of Leuven
  • Developer BioInvent International; ThromboGenics
  • Class Anticoagulants; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Factor VIII inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Venous thromboembolism

Most Recent Events

  • 05 Jun 2012 Discontinued - Phase-II for Venous thromboembolism in European Union (IV, Infusion)
  • 05 Jun 2012 Discontinued - Phase-II for Venous thromboembolism in European Union (IV, Injection)
  • 05 Jun 2012 Discontinued - Phase-II for Venous thromboembolism in Israel (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top